Capricor Therapeutics Inc Stock
Capricor Therapeutics Inc took a tumble today and lost -€0.121 (-3.340%).
Our community identified positive and negative aspects for Capricor Therapeutics Inc stock for the coming years. 0 users see the criterium "Return on equity" as a plus for the Capricor Therapeutics Inc stock. On the other hand our users think that "Return on equity" could be a problem in the future.
Pros and Cons of Capricor Therapeutics Inc in the next few years
Pros
?
S********** s********
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Capricor Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | -3.340% | -79.249% | -82.814% | -49.498% | -85.883% | -11.359% | -1.603% |
| Evolus Inc | -0.040% | -0.954% | -14.526% | -33.462% | -4.771% | -42.967% | -41.356% |
| Heron Therapeutics Inc. | 1.530% | 3.155% | 15.773% | -72.386% | -61.257% | -69.171% | -95.838% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
News
This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?
Karen Krasney, EVP, General Counsel of Capricor Therapeutics (NASDAQ:CAPR), reported the exercise of 24,100 stock options and immediate sale of the underlying common shares for a total transaction
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Key Points
- Interested in Capricor Therapeutics, Inc.? Here are five stocks we like better.
- Capricor Therapeutics says it is in active discussions with the FDA to support approval of deramiocel
Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review